Analytical Data
-
基因名
ST6GAL1
- Application
-
别名
B-cell antigen CD75 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1 ST6Gal I
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15907
-
表达区间
1-406aa
-
分子量
52.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ST6GAL1, also known as ST6 beta-galactosamide alpha-2,6-sialyltransferase 1, is an important enzyme involved in the biosynthesis of sialylated glycan structures on glycoproteins and glycolipids. Sialic acids are key components that modulate cellular interactions, immune responses, and the stability of glycoproteins. Dysregulation of ST6GAL1 has been implicated in various biological processes, including cancer progression, as it influences tumor cell behavior and the immune evasion mechanisms of cancer cells. Additionally, ST6GAL1 plays a crucial role in neuronal development and function, making its study relevant in neuroscientific research. Recent advancements in recombinant protein technology have enabled the production of ST6GAL1 in heterologous systems, allowing for a better understanding of its function and mechanisms. By studying the recombinant form of ST6GAL1, researchers aim to elucidate its specific role in sialic acid transfer, the resulting effects on glycan structures, and its implications in health and disease. This research holds significance not only for basic science but also for potential therapeutic interventions targeting ST6GAL1 in diseases associated with altered sialylation patterns.
